Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fulvestrant - AstraZeneca

Drug Profile

Fulvestrant - AstraZeneca

Alternative Names: Faslodex; ICI 182780; ZD 182780; ZD 9238; ZM 182780

Latest Information Update: 01 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Baylor Research Institute; Eli Lilly and Company
  • Class Antineoplastics; Estradiol congeners; Estrenes
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Precocious puberty
  • No development reported Endometrial cancer
  • Discontinued Endometriosis

Most Recent Events

  • 29 Sep 2019 Updated efficacy and adverse data from the phase III MONARCH 2 trial in Breast cancer presented at the 44th European Society for Medical Oncology Congress (ESMO-2019)
  • 13 Aug 2019 Phase-II clinical trials in Fallopian tube cancer (Combination therapy, Late-stage disease, Metastatic disease, Neoadjuvant therapy) in USA (IM) (NCT03531645)
  • 13 Aug 2019 Phase-II clinical trials in Ovarian cancer (Combination therapy, Late-stage disease, Metastatic disease, Neoadjuvant therapy) in USA (IM) (NCT03531645)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top